Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quanterra

This article was originally published in The Tan Sheet

Executive Summary

Herbal supplement line discontinued as of Sept. 30, Pfizer's Warner-Lambert Consumer Group announces, citing sales declines for the brand and in the overall herbal category. Quanterra launched in 1998 with three products - Mental Sharpness, Emotional Balance and Prostate. W-L subsequently made several efforts to boost sales, including expanding distribution to nutritional centers such as GNC and doubling the line's size with the additions of Stomach Comfort, Sinus Defense and Sleep. The line had sales of $7.5 mil. in food, drug and mass channels for the 52 weeks ending Aug. 20, down 9.5% from the year-ago period, IRI data indicate

You may also be interested in...



Pfizer “naturaceuticals”

Consumer Healthcare division working with Global R&D on "'naturaceuticals,' effective natural products that might be difficult to develop as an Rx molecule, but might come to market relatively quickly under OTC or food supplement regulations," Consumer Healthcare Head Maurice Renshaw says in recent Pfizer employee newsletter. Pfizer's only U.S. supplement offerings are Halls Defense Supplement Drops; firm discontinued Quanterra supplement line in September 2000 due to low sales (1"The Tan Sheet" Oct. 2, 2000, In Brief). Renshaw says addition of Pharmacia's consumer healthcare business will add "geographic presence in important areas, including Western Europe - particularly the Nordic region - and Japan." Pfizer's acquisition of Pharmacia is expected to close by year-end...

Pfizer “naturaceuticals”

Consumer Healthcare division working with Global R&D on "'naturaceuticals,' effective natural products that might be difficult to develop as an Rx molecule, but might come to market relatively quickly under OTC or food supplement regulations," Consumer Healthcare Head Maurice Renshaw says in recent Pfizer employee newsletter. Pfizer's only U.S. supplement offerings are Halls Defense Supplement Drops; firm discontinued Quanterra supplement line in September 2000 due to low sales (1"The Tan Sheet" Oct. 2, 2000, In Brief). Renshaw says addition of Pharmacia's consumer healthcare business will add "geographic presence in important areas, including Western Europe - particularly the Nordic region - and Japan." Pfizer's acquisition of Pharmacia is expected to close by year-end...

Pfizer “naturaceuticals”

Consumer Healthcare division working with Global R&D on "'naturaceuticals,' effective natural products that might be difficult to develop as an Rx molecule, but might come to market relatively quickly under OTC or food supplement regulations," Consumer Healthcare Head Maurice Renshaw says in recent Pfizer employee newsletter. Pfizer's only U.S. supplement offerings are Halls Defense Supplement Drops; firm discontinued Quanterra supplement line in September 2000 due to low sales (1"The Tan Sheet" Oct. 2, 2000, In Brief). Renshaw says addition of Pharmacia's consumer healthcare business will add "geographic presence in important areas, including Western Europe - particularly the Nordic region - and Japan." Pfizer's acquisition of Pharmacia is expected to close by year-end...

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel